[1].Rodriguez, M., Siva, A., Ward, J., et al. (1994).” Impairment, Disability, and Handicap in Multiple Sclerosis: A Population-based Study in Olmsted County Minnesota” . Neurology, Vol.44, PP. 28–33.
[2].Hauser, S.(1994).” Multiple Sclerosis and other Ddemyelinating Diseases In: Isselbacher K.J, Martin., J.B, Fauci A.S., et al, eds” . Harrison’s Principles of Internal Medicine, New York: McGraw-Hill, PP. 2287–2953.
[3].Oksenberg, J.R., Hauser, S.L.(2005).”Genetics of Multiple Sclerosis” .Neurology Clinic, Vol. 23, PP. 61–75.
[4].Bagert, B., Camplair, P., Bourdette, D.(2002).” Cognitive Dysfunction in Multiple Sclerosis: Natural History, Pathophysiology and Management ” . CNS Drugs, Vol.16, PP. 445–455.
[5].Weinshenker, BG., Bass, B., Rice, G.P,. et al. (1989).” The Natural History of Multiple Sclerosis: A Geographically Based Study, Clinical Course and Disability” . Brain, Vol.112, PP.133–146.
[6] Montalban, X., (2005).” Primary Progressive Multiple Sclerosis” .Current Opinion Neurology, Vol.18, PP. 261–266.
[7].Lublin, F.D., Reingold, SC.(1996).” Defining the Clinical Course of Multiple Sclerosis: Results of an International Survey” , National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology, Vol.46, PP. 907–911.
[8].Barkhof, F., Filippi, M., Miller, DH., et al.(1997). ”Comparison of MRI Criteria at First Presentation to Predict Conversion to Clinically Definite Multiple Sclerosis” . Brain, Vol.120, PP. 2059–2069.
[9]McDonald, W.I., Compston, A., Edan, G., et al.(2001).” Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis” . Annual Neurology. Vol. 50, PP. 121–127.
[10].Poser, CM.(1987).” Diagnostic Criteria for Multiple Sclerosis: An Addendum” . Annual Neurology, Vol. 22, PP. 773.
[11].Tintore, M., Rovira, A., Martinez, M.J., et al.(2000).” Isolated Demyelinating Syndromes: Comparison of Different MR Imaging Criteria to Predict Conversion to Clinically Definite Multiple Sclerosis” . American Journal of Neuro-Radiology. Vol. 21, PP. 702–706.
[12].Bot, J.C., Barkhof, F., Lycklama, A., Nijeholt, G., et al.(2002).” Differentiation of Multiple Sclerosis from other Inflammatory Disorders and Cerebrovascular Disease: Value of Spinal MR Imaging. Radiology, Vol. 223, PP. 46–56.
[13].Pashenkov, M., Teleshova ,N., Link, H.(2003).” Inflammation in the Central Nervous System: the Role for Dendritic Cells” . Brain Pathology, Vol. 13, PP. 23–33.
[14]. Hafler, D.A., Slavik, J.M., Anderson, D.E., et al. (2005).” Multiple Sclerosis” . Immunol Review”, Vol. 204, PP. 208–231.
[15] Link,. H.(1998).” The Cytokine Storm in Multiple Sclerosis” . Multiple Sclerosis, Vol. 4, PP. 12–15.
[16] Lassmann, H.(1998).” Pathology of Multiple Sclerosis. In: Compston A, Ebers, G., Lassmann, H., et al, eds” . McAlpine’s Multiple Sclerosis. London: Churchill Livingstone, PP. 323–357.
[17] Steinman, L. (2001).” Multiple Sclerosis: A Two-Stage Disease” . Nature Immunology, Vol. 2, PP. 762– 764.
[18] Lassmann, H., Bruck, W., Lucchinett, C. (2001).”Heterogeneity of Multiple Sclerosis Pathogenesis: Implicationsfor Diagnosis and Therapy” , Trends Mol Med, Vol. 7, PP. 115–121.
[19]. Lassmann, H.(2003).” Hypoxia-like Tissue Injury as a Component of Multiple Sclerosis Lesions” . Neurol Sci. Vol. 206, PP. 187–191.
[20]Trapp, BD., Ransohoff, R., Rudick, R.(1999).” Axonal Pathology in Multiple sclerosis: Relationship to Neurologic Disability” . Curr Opin Neurol, Vol. 12, PP.295–302.
[21].Kapoor, R., Davies, M., Blaker, P.A., et al. (2003).” Blockers of Sodium and Calcium Entry Protect Axons from Nitric Oxide-Mediated Degeneration” . Annual Neurology, Vol. 53, PP. 174–180.
[22]. Werner, P., Pitt D., Raine, C.S.(2001). ” Multiple Sclerosis: Altered Glutamate Homeostasis in Lesions Correlates with Oligodendrocyte and Axonal Damage”. Annual Neurology, Vol. 50, PP. 169–180.
[23]Craner, M.J., Newcombe, J., Black, J.A., et al.(2004).” Molecular Changes in Neurons in Multiple Sclerosis: Altered Axonal Expression of Nav1.2 and Nav1.6 Sodium Channels and Na+/Ca2+ exchanger” . Proc Natl Acad Sci. USA, Vol. 101, PP. 8168–8173.
[24].Bo. L., Vedeler, C.A., Nyland, H., et al.(2003).” Intracortical Multiple Sclerosis Lesions are not Associated with Increased Lymphocyte Infiltration” , Multiple Sclerosis, Vol. 9, PP. 323–331.
[25].Peterson ,J.W., Bo, L., Mork, S., et al.(2001).” Transected Neurites, Apoptotic Neurons, and Reduced Inflammation in Cortical Multiple Sclerosis Lesions”. Annaul Neurology, Vol. 50, PP. 389–400.
[26].Olek, M.J.(2010).”Treatment of Relapsing-RemittingMultiple Sclerosis in Adults. ( http://www. uptodate.com/home/index.html ).
[27].Cotran, R.S., Kumar, V., Collins, T. (Robbins):(1999).” Pathologic Basis of Disease” , Chapter 30, 6th edition, PP. 1326-1327.
[28]. Parsa, N., Gaidano, G., Mukherjee, A., Hauptschein, R., Lenoir, G., Dalla-Favera, R., et al.(1994).” Cytogenetic and Molecular Analysis of 6q Deletions in Burkitt’s Lymphoma Cell lines” . Genes Chromosomes Cancer, Vol. 9, No.1. PP. 13-18.
[29].Papanicolaou, G.J., Parsa, N., Meltzer, P.S., Trent, J.M.(1997).” Assignment of Interferon Gamma Receptor to Human Chromosome Bands 6q24.1- q24.2 by Fluorescence In Situ Hybridization FISH)” . Journal of Cytogenetics and Cell Genetics, Vol. 76, PP. 181-182.